GlobeNewswire Inc | Nov 3, 2021 08:30AM EDT

November 03, 2021

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 10, 2021, to provide a corporate update and discuss the Companys financial results for the third quarter ended September 30, 2021.

Conference call and webcast details:

Investors (domestic): (877) 705-6003Investors (international): (201) 493-6725Conference ID: 13724235Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1504710&tp_key=3a6a6b5742

A live audio webcast can be accessed by visiting the Investor Relations section of the Companys website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

AboutSCYNEXIS

SCYNEXIS, Inc.(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the companys lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME(ibrexafungerp tablets), which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, late-stage clinical development of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visitwww.scynexis.com.

CONTACT

Investor RelationsIrina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

Media RelationsGloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com